CA2417935C - Anti-inflammatory medicament - Google Patents
Anti-inflammatory medicament Download PDFInfo
- Publication number
- CA2417935C CA2417935C CA2417935A CA2417935A CA2417935C CA 2417935 C CA2417935 C CA 2417935C CA 2417935 A CA2417935 A CA 2417935A CA 2417935 A CA2417935 A CA 2417935A CA 2417935 C CA2417935 C CA 2417935C
- Authority
- CA
- Canada
- Prior art keywords
- oatp
- atp
- paws
- injection
- inflammatory
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 7
- 230000003110 anti-inflammatory effect Effects 0.000 title description 4
- MWEQTWJABOLLOS-UHFFFAOYSA-L disodium;[[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-oxidophosphoryl] hydrogen phosphate;trihydrate Chemical compound O.O.O.[Na+].[Na+].C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP([O-])(=O)OP(O)([O-])=O)C(O)C1O MWEQTWJABOLLOS-UHFFFAOYSA-L 0.000 claims abstract description 5
- 208000002193 Pain Diseases 0.000 claims description 7
- 230000036407 pain Effects 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 3
- 238000007911 parenteral administration Methods 0.000 claims description 2
- 238000011200 topical administration Methods 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims description 2
- 230000004968 inflammatory condition Effects 0.000 abstract description 2
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 29
- 238000002347 injection Methods 0.000 description 22
- 239000007924 injection Substances 0.000 description 22
- 241000700159 Rattus Species 0.000 description 18
- 210000002683 foot Anatomy 0.000 description 15
- 230000003040 nociceptive effect Effects 0.000 description 12
- 230000004054 inflammatory process Effects 0.000 description 11
- 206010061218 Inflammation Diseases 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 230000000202 analgesic effect Effects 0.000 description 6
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 6
- 229960001259 diclofenac Drugs 0.000 description 6
- 230000002757 inflammatory effect Effects 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 206010020843 Hyperthermia Diseases 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000036031 hyperthermia Effects 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 208000004454 Hyperalgesia Diseases 0.000 description 3
- 208000035154 Hyperesthesia Diseases 0.000 description 3
- 102100037602 P2X purinoceptor 7 Human genes 0.000 description 3
- 101710189965 P2X purinoceptor 7 Proteins 0.000 description 3
- 229940124599 anti-inflammatory drug Drugs 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000000548 hind-foot Anatomy 0.000 description 3
- 206010033675 panniculitis Diseases 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 210000004304 subcutaneous tissue Anatomy 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 231100000582 ATP assay Toxicity 0.000 description 2
- 230000002407 ATP formation Effects 0.000 description 2
- 206010051392 Diapedesis Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 230000003502 anti-nociceptive effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000001461 cytolytic effect Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000002796 luminescence method Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 208000000114 Pain Threshold Diseases 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 239000002262 Schiff base Substances 0.000 description 1
- 150000004753 Schiff bases Chemical class 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000037041 intracellular level Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000002025 microglial effect Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000037040 pain threshold Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical class OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000010118 platelet activation Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 230000020341 sensory perception of pain Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61G—TRANSPORT, PERSONAL CONVEYANCES, OR ACCOMMODATION SPECIALLY ADAPTED FOR PATIENTS OR DISABLED PERSONS; OPERATING TABLES OR CHAIRS; CHAIRS FOR DENTISTRY; FUNERAL DEVICES
- A61G17/00—Coffins; Funeral wrappings; Funeral urns
- A61G17/04—Fittings for coffins
- A61G17/041—Handles
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Cartons (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITMI2000A001827 | 2000-08-04 | ||
| IT2000MI001827A IT1318667B1 (it) | 2000-08-04 | 2000-08-04 | Medicamento antinfiammatorio. |
| PCT/EP2001/008643 WO2002011737A2 (en) | 2000-08-04 | 2001-07-26 | Anti-inflammatory medicament |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2417935A1 CA2417935A1 (en) | 2002-02-14 |
| CA2417935C true CA2417935C (en) | 2010-04-20 |
Family
ID=11445671
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2417935A Expired - Fee Related CA2417935C (en) | 2000-08-04 | 2001-07-26 | Anti-inflammatory medicament |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US7317018B2 (OSRAM) |
| EP (1) | EP1305037B1 (OSRAM) |
| JP (1) | JP2004505922A (OSRAM) |
| AT (1) | ATE360428T1 (OSRAM) |
| AU (1) | AU2001293707A1 (OSRAM) |
| CA (1) | CA2417935C (OSRAM) |
| DE (1) | DE60128100T2 (OSRAM) |
| DK (1) | DK1305037T3 (OSRAM) |
| ES (1) | ES2284695T3 (OSRAM) |
| IT (1) | IT1318667B1 (OSRAM) |
| MX (1) | MXPA03001081A (OSRAM) |
| PT (1) | PT1305037E (OSRAM) |
| RU (1) | RU2281105C2 (OSRAM) |
| WO (1) | WO2002011737A2 (OSRAM) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7234211B2 (en) * | 2003-07-23 | 2007-06-26 | Vandor Corporation | Mortise and tenon casket with pins |
| ITMI20040255A1 (it) * | 2004-02-17 | 2004-05-17 | Univ Degli Studi Milano | Sostanze ad attivita' antiangiogenica |
| FR2886541B1 (fr) * | 2005-06-06 | 2008-08-22 | Rolavie Sarl | Cercueil en carton, bois ou materiau analogue, a entree laterale |
| JP5241255B2 (ja) * | 2008-02-01 | 2013-07-17 | 生化学工業株式会社 | 関節痛の評価方法 |
| US20090241309A1 (en) * | 2008-03-31 | 2009-10-01 | Venus Valeta Smith | Environmentally safe fantasy coffin/caskets |
| US8347467B2 (en) * | 2009-07-03 | 2013-01-08 | Vandor Corporation | Lightweight viewing casket with reinforcing lid and method of using same |
| US8151421B2 (en) * | 2010-08-17 | 2012-04-10 | Liang Le Hsu | Foldable paper coffin |
| ITTO20110652A1 (it) * | 2011-07-20 | 2013-01-21 | Medestea Res & Production S P A | Composto derivato dall'adenina avente azione immuno-modulante, antinfiammatoria e antidolorifica |
| US8918969B2 (en) * | 2012-10-29 | 2014-12-30 | Charles T Jenson | Funeral container carrying device |
| NL2010192C2 (en) * | 2013-01-28 | 2014-08-04 | Rolandus Franciscus Beatrijs Marie Josef Hoijng | Coffin for holding an inner coffin and having a base and a cover. |
| WO2014182601A1 (en) * | 2013-05-08 | 2014-11-13 | Children's Medical Center Corporation | A method of preventing and treating type 1 diabetes, allograft rejection and lung fibrosis (by targeting the atp/p2x7r axis) |
| US9364381B1 (en) * | 2013-07-01 | 2016-06-14 | Charles Lunt | Handy handle systems |
| WO2020181139A1 (en) * | 2019-03-05 | 2020-09-10 | Bedford Systems Llc | Spring biased box clip |
| US11638671B2 (en) * | 2021-09-10 | 2023-05-02 | Jennifer Trammell | Mycelium composite burial container |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US626432A (en) * | 1899-06-06 | Casket-carrier | ||
| US520015A (en) * | 1894-05-15 | Detachable casket-handle | ||
| AU399705B (en) | 1905-08-28 | 1905-11-28 | Herbert Hyatt William | Improvements ingold extraction |
| US2494473A (en) * | 1944-07-29 | 1950-01-10 | Plastic Products Corp | Plastic casket |
| US2723073A (en) * | 1953-03-27 | 1955-11-08 | Bankers Box Company | Collapsible filing container |
| US2992768A (en) * | 1958-07-04 | 1961-07-18 | Gatward Harry Frederick | Carrier bags and boxes |
| US3220080A (en) * | 1962-04-10 | 1965-11-30 | Connelly Containers Inc | Fiber board coffin |
| CH413231A (de) * | 1963-10-04 | 1966-05-15 | Schneider Erich | Sarg aus Kunststoff |
| FR1569802A (OSRAM) | 1968-04-01 | 1969-06-06 | ||
| US3900157A (en) * | 1974-03-19 | 1975-08-19 | Herman P Roth | Tub file |
| GB8920880D0 (en) * | 1989-09-14 | 1989-11-01 | Grant Martin F | A releasable connector |
| CH689295A5 (fr) * | 1993-09-28 | 1999-02-15 | Gerald Pidoux | Cercueil pliable. |
| US5847135A (en) * | 1994-06-17 | 1998-12-08 | Vertex Pharmaceuticals, Incorporated | Inhibitors of interleukin-1β converting enzyme |
| KR100517210B1 (ko) * | 1994-12-12 | 2006-06-07 | 오메로스 코포레이션 | 통증,염증및경련억제용관주용액 |
| US5694746A (en) * | 1994-12-20 | 1997-12-09 | Chung; Yun H. | Paperboard package and method for forming same |
| US5823424A (en) * | 1996-01-25 | 1998-10-20 | Wallace Packaging Corporation | Foldable box with insert |
| US6096728A (en) * | 1996-02-09 | 2000-08-01 | Amgen Inc. | Composition and method for treating inflammatory diseases |
| US6039243A (en) * | 1997-10-14 | 2000-03-21 | Lickton; Robert J. | Collapsible shipping container |
| US20040104264A1 (en) * | 2003-08-15 | 2004-06-03 | Meeker R And D, Inc. | Container closure device and method |
-
2000
- 2000-08-04 IT IT2000MI001827A patent/IT1318667B1/it active
-
2001
- 2001-07-26 AT AT01974088T patent/ATE360428T1/de not_active IP Right Cessation
- 2001-07-26 JP JP2002517073A patent/JP2004505922A/ja not_active Ceased
- 2001-07-26 DE DE60128100T patent/DE60128100T2/de not_active Expired - Lifetime
- 2001-07-26 ES ES01974088T patent/ES2284695T3/es not_active Expired - Lifetime
- 2001-07-26 PT PT01974088T patent/PT1305037E/pt unknown
- 2001-07-26 US US10/343,756 patent/US7317018B2/en not_active Expired - Fee Related
- 2001-07-26 MX MXPA03001081A patent/MXPA03001081A/es active IP Right Grant
- 2001-07-26 EP EP01974088A patent/EP1305037B1/en not_active Expired - Lifetime
- 2001-07-26 WO PCT/EP2001/008643 patent/WO2002011737A2/en not_active Ceased
- 2001-07-26 RU RU2003105901/15A patent/RU2281105C2/ru not_active IP Right Cessation
- 2001-07-26 DK DK01974088T patent/DK1305037T3/da active
- 2001-07-26 CA CA2417935A patent/CA2417935C/en not_active Expired - Fee Related
- 2001-07-26 AU AU2001293707A patent/AU2001293707A1/en not_active Abandoned
- 2001-07-30 US US10/343,739 patent/US7213312B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| AU2001293707A1 (en) | 2002-02-18 |
| DE60128100D1 (de) | 2007-06-06 |
| ITMI20001827A1 (it) | 2002-02-04 |
| MXPA03001081A (es) | 2003-10-15 |
| RU2281105C2 (ru) | 2006-08-10 |
| WO2002011737A3 (en) | 2002-05-02 |
| WO2002011737A2 (en) | 2002-02-14 |
| US7317018B2 (en) | 2008-01-08 |
| ATE360428T1 (de) | 2007-05-15 |
| US20040023920A1 (en) | 2004-02-05 |
| US20040098847A1 (en) | 2004-05-27 |
| EP1305037B1 (en) | 2007-04-25 |
| US7213312B2 (en) | 2007-05-08 |
| ITMI20001827A0 (it) | 2000-08-04 |
| DE60128100T2 (de) | 2008-01-10 |
| PT1305037E (pt) | 2007-07-20 |
| EP1305037A2 (en) | 2003-05-02 |
| IT1318667B1 (it) | 2003-08-27 |
| CA2417935A1 (en) | 2002-02-14 |
| ES2284695T3 (es) | 2007-11-16 |
| DK1305037T3 (da) | 2007-09-17 |
| JP2004505922A (ja) | 2004-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2417935C (en) | Anti-inflammatory medicament | |
| Ockaili et al. | Sildenafil (Viagra) induces powerful cardioprotective effect via opening of mitochondrial KATP channels in rabbits | |
| Sheehan et al. | Parthenolide, an inhibitor of the nuclear factor-κB pathway, ameliorates cardiovascular derangement and outcome in endotoxic shock in rodents | |
| US5658889A (en) | Method and compounds for aica riboside delivery and for lowering blood glucose | |
| Kowaluk et al. | ABT-702 (4-amino-5-(3-bromophenyl)-7-(6-morpholino-pyridin-3-yl) pyrido [2, 3-d] pyrimidine), a novel orally effective adenosine kinase inhibitor with analgesic and anti-inflammatory properties. II. In vivo characterization in the rat | |
| EP0427799B1 (en) | Method and compounds for aica riboside delivery and for lowering blood glucose | |
| Urban et al. | In vivo pharmacology of SDZ 249-665, a novel, non-pungent capsaicin analogue | |
| US20070060638A1 (en) | Methods and therapies for potentiating therapeutic activities of a cannabinoid receptor agonist via administration of a cannabinoid receptor antagonist | |
| Impagnatiello et al. | Intraocular pressure–lowering activity of NCX 470, a novel nitric oxide–donating bimatoprost in preclinical models | |
| JP2013166789A (ja) | 骨関節炎の治療におけるａ３アデノシン受容体アゴニストの使用 | |
| KR20090094090A (ko) | 치료를 위한 방법 및 조성물 | |
| RS64402B1 (sr) | Lečenje bola povezanog sa dijabetičkom perifernom neuropatijom | |
| KR20080035997A (ko) | 글루코사민 또는 글루코사민 유도체를 포함하는 아토피성피부염 치료용 조성물 및 이를 사용하여 아토피성 피부염을치료하는 방법 | |
| Jarvis et al. | Comparison of the ability of adenosine kinase inhibitors and adenosine receptor agonists to attenuate thermal hyperalgesia and reduce motor performance in rats | |
| EP0772440A4 (en) | CARBON MONOXIDE DEPENDENT GUANYL CYCLASE MODIFICATORS | |
| AU2005310874B2 (en) | Treatment of inflammation | |
| KR0133555B1 (ko) | 5-플루오로우라실계 화합물에 기인한 염증의 발생을 억제할 수 있는 비-주사제 형태의 항암조성물 | |
| Alonso et al. | Nitric-oxide-related and non-related mechanisms in the acetylcholine-evoked relaxations in cat femoral arteries | |
| US20140094446A1 (en) | Cyclic Amino Acids for the Treatment of Pain | |
| Pagea et al. | Characterization of both dopamine uptake systems in rat striatal slices by specific pharmacological tools | |
| US20230277569A1 (en) | Compositions and Methods for Treating, Ameliorating and/or Preventing Cancer and Kits for the Same | |
| Bass et al. | Embryonic development and mitochondrial function: 2. Thiamphenicol Induced Embryotoxicity | |
| Dallessio et al. | Reduction of bleomycin-induced acute DNA injury in the rat lung by the 21-aminosteroid, U-74389G | |
| Li | Elucidation of the signaling pathway that mediates anxiolytic effects of nitrous oxide | |
| Szabó | Role of peroxynitrite and poly-(ADP-ribose) synthetase in shock, inflammation, and ischemia-reperfusion injury |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |